A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

• Status: Not yet recruiting
• Trial end date: 2023-08-27
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to assess the effect of BMS-986196 on the drug levels of caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin in healthy participants.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Caffeine; Digoxin; Flurbiprofen; Midazolam; Montelukast; Omeprazole; Pravastatin

Criteria

Inclusion Criteria:

• Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations.

• Body mass index of 18.0 to 33.0 kilogram per meter squared (kg/m^2), inclusive, and body weight ≥50.0 kg.

Exclusion Criteria:

• History of rhabdomyolysis.

• History of peptic ulcer disease or significant GI bleeding.

• History of malignancy in the 5 years prior to screening (except fully excised basal cell carcinoma).